About lantern pharma inc - LTRN
Lantern Pharma, Inc. engages in the development of drugs through leveraging artificial intelligence, machine learning, and genomic data. Its portfolio includes LP-100, LP-300, and LP-184. The company was founded by Arun K. Asaithambi, Gregory T. Tobin, and Peter L. Nara on November 7, 2013 and is headquartered in Dallas, TX.
LTRN At a Glance
Lantern Pharma, Inc.
1920 McKinney Avenue
Dallas, Texas 75201
| Phone | 1-972-277-1136 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -17,119,438.00 | |
| Sector | Health Technology | Employees | 16 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
LTRN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 5.219 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.279 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.003 |
LTRN Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,069,964.875 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
LTRN Liquidity
| Current Ratio | 2.40 |
| Quick Ratio | 2.40 |
| Cash Ratio | 2.248 |
LTRN Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -93.52 |
| Return on Equity | -123.508 |
| Return on Total Capital | -258.885 |
| Return on Invested Capital | -123.273 |
LTRN Capital Structure
| Total Debt to Total Equity | 1.202 |
| Total Debt to Total Capital | 1.188 |
| Total Debt to Total Assets | 0.711 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |